351 related articles for article (PubMed ID: 29889414)
1. Links between genetics and immunology: mutations and antigens.
Ayyoub M
Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414
[TBL] [Abstract][Full Text] [Related]
2. The role of neoantigens in response to immune checkpoint blockade.
Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
[TBL] [Abstract][Full Text] [Related]
3. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
4. Neoantigens in cancer immunotherapy.
Schumacher TN; Schreiber RD
Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
[TBL] [Abstract][Full Text] [Related]
5. Study May Change Approach to Immunotherapy.
Cancer Discov; 2016 May; 6(5):OF1. PubMed ID: 27012834
[TBL] [Abstract][Full Text] [Related]
6. Cancer Neoantigens and Applications for Immunotherapy.
Desrichard A; Snyder A; Chan TA
Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495
[TBL] [Abstract][Full Text] [Related]
7. Targeting neoantigens to augment antitumour immunity.
Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
[TBL] [Abstract][Full Text] [Related]
8. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V; Rosenberg SA
Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
10. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
Yin Q; Tang J; Zhu X
Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
[TBL] [Abstract][Full Text] [Related]
12. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
13. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
Bethune MT; Joglekar AV
Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
15. New emerging targets in cancer immunotherapy: the role of neoantigens.
De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J
ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031
[TBL] [Abstract][Full Text] [Related]
16. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
[TBL] [Abstract][Full Text] [Related]
17. T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors.
Sioud M
Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29381830
[TBL] [Abstract][Full Text] [Related]
18. Tumor immunology.
Shu S; Plautz GE; Krauss JC; Chang AE
JAMA; 1997 Dec; 278(22):1972-81. PubMed ID: 9396660
[TBL] [Abstract][Full Text] [Related]
19. Neoantigens in the immuno-oncology space.
Arlen PM
Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
[No Abstract] [Full Text] [Related]
20. Cancer Neoantigens.
Schumacher TN; Scheper W; Kvistborg P
Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
